Company intelligence / Profile preview

Genomadix

Ottawa, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

The Genomadix Cube qPCR platform is commercialized with FDA 510(k)-cleared and CE-marked rapid CYP2C19 genotyping, environmental water testing for Legionella, and RUO ApoE genotyping assays; clinical development pipeline not reported[1][3].

Therapeutic areas: Infectious DiseasesNeurologyOther
Modalities: DeviceqPCR platformMolecular diagnostics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Genomadix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomadix.

Explore the full profile